Elegant Pharma Marketing Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-12-2024
- Paid Up Capital ₹ 0.23 M
as on 15-12-2024
- Company Age 27 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 24.21%
(FY 2022)
- Profit 102.65%
(FY 2022)
- Ebitda 39.99%
(FY 2022)
- Net Worth 6.98%
(FY 2022)
- Total Assets -15.07%
(FY 2022)
About Elegant Pharma Marketing
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.23 M, as per Ministry of Corporate Affairs (MCA) records.
Kashinath Das, Debabrata Sarkar, and Sayantan Bhattacharya serve as directors at the Company.
- CIN/LLPIN
U24232WB1997PTC085725
- Company No.
085725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Elegant Pharma Marketing?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kashinath Das  | Director | 30-Oct-1997 | Current |
| Debabrata Sarkar | Director | 20-Oct-1997 | Current |
| Sayantan Bhattacharya | Director | 01-Jul-2008 | Current |
Financial Performance of Elegant Pharma Marketing.
Elegant Pharma Marketing Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.21% increase. The company also saw a substantial improvement in profitability, with a 102.65% increase in profit. The company's net worth moved up by a moderate rise of 6.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elegant Pharma Marketing?
In 2017, Elegant Pharma Marketing had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Classic Designer & Developer Pvt.Ltd.Active 29 years 2 monthsDebabrata Sarkar and Sayantan Bhattacharya are mutual person
- Kingfisher East Bengal Football Team Private LimitedActive 26 years 9 months
Debabrata Sarkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elegant Pharma Marketing?
Elegant Pharma Marketing has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elegant Pharma Marketing, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elegant Pharma Marketing's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
